Molecular Docking Identifies 1,8-Cineole (Eucalyptol) as A Novel PPARγ Agonist That Alleviates Colon Inflammation

Inflammatory bowel disease, comprising Crohn's disease (CD) and ulcerative colitis (UC), is often debilitating. The disease etiology is multifactorial, involving genetic susceptibility, microbial dysregulation, abnormal immune activation, and environmental factors. Currently, available drug therapies are associated with adverse effects when used long-term. Therefore, the search for new drug candidates to treat IBD is imperative. The peroxisome proliferator-activated receptor-? (PPAR?) is highly expressed in the colon. PPAR? plays a vital role in regulating colonic inflammation. 1,8-cineole, also known as eucalyptol, is a monoterpene oxide present in various aromatic plants which possess potent anti-inflammatory activity. Molecular docking and dynamics studies revealed that 1,8-cineole binds to PPAR? and if it were an agonist, that would explain the anti-inflammatory effects of 1,8-cineole. Therefore, we investigated the role of 1,8-cineole in colonic inflammation, using both in vivo and in vitro experimental approaches. Dextran sodium sulfate (DSS)-induced colitis was used as the in vivo model, and tumor necrosis factor-a (TNFa)-stimulated HT-29 cells as the in vitro model. 1,8-cineole treatment significantly decreased the inflammatory response in DSS-induced colitis mice. 1,8-cineole treatment also increased nuclear factor erythroid 2-related factor 2 (Nrf2) translocation into the nucleus to induce potent antioxidant effects. 1,8-cineole also increased colonic PPAR? protein expression. Similarly, 1,8-cineole decreased proinflammatory chemokine production and increased PPAR? protein expression in TNFa-stimulated HT-29 cells. 1,8-cineole also increased PPAR? promoter activity time-dependently. Because of its potent anti-inflammatory effects, 1,8-cineole may be valuable in treating IBD.

Automated summary

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a debilitating condition with a multifactorial etiology. Current drug therapies for IBD have adverse effects with long-term use, thus the need for new drug candidates. 1,8-cineole, a monoterpene oxide, has potent anti-inflammatory effects through binding to PPAR?. Studies have shown that 1,8-cineole can decrease inflammation, induce antioxidant effects, and increase PPAR? expression. Due to its strong anti-inflammatory effects, 1,8-cineole may be valuable in treating IBD.